文献速递细菌感染、耐药与抗菌药物

2015-18年突尼斯、肯尼亚和摩洛哥抗生素耐药性调查(SOAR):基于CLSI、EUCAST(剂量特异性)和PK/PD折点的数据

Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究测定了2015-18年突尼斯、肯尼亚和摩洛哥社区获得性呼吸道感染分离的肺炎链球菌和流感嗜血杆菌的MIC,并用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。结果显示突尼斯肺炎链球菌敏感性低,肯尼亚较高,摩洛哥最高;突尼斯流感嗜血杆菌对多数抗生素高度敏感。

要点

  • 突尼斯肺炎链球菌仅对氟喹诺酮类、青霉素(CLSI IV和EUCAST高剂量)和头孢曲松(CLSI、EUCAST高剂量和PK/PD折点)敏感性>90%。
  • 摩洛哥肺炎链球菌对多数抗生素敏感性≥89.5%,但对甲氧苄啶/磺胺甲噁唑、大环内酯类和头孢克洛敏感性较低。
  • 突尼斯流感嗜血杆菌对多数抗生素敏感性≥86.5%,但对氨苄西林、阿莫西林、甲氧苄啶/磺胺甲噁唑、头孢克洛、头孢呋辛、大环内酯类和头孢地尼敏感性低。

核心结论

  • 突尼斯肺炎链球菌抗生素敏感性低,肯尼亚较高,摩洛哥最高;突尼斯流感嗜血杆菌对多数抗生素高度敏感,这些因素对社区获得性呼吸道感染经验性治疗决策重要。

研究设计与样本

  • 研究测定了2015-18年从突尼斯、肯尼亚和摩洛哥社区获得性呼吸道感染中收集的肺炎链球菌和流感嗜血杆菌分离株的MIC,采用CLSI broth microdilution法,并使用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。
  • 肺炎链球菌分离株来自突尼斯(n=79)、肯尼亚(n=44)和摩洛哥(n=19),流感嗜血杆菌分离株仅来自突尼斯(n=74)。

主要发现

  • 突尼斯肺炎链球菌对氟喹诺酮类(所有折点)、青霉素(CLSI IV和EUCAST高剂量)和头孢曲松(CLSI、EUCAST高剂量和PK/PD折点)敏感性>90%。
  • 肯尼亚肺炎链球菌对阿莫西林和阿莫西林/克拉维酸(CLSI和PK/PD折点)敏感性>90%。
  • 摩洛哥肺炎链球菌对多数抗生素敏感性≥89.5%,但对甲氧苄啶/磺胺甲噁唑(CLSI或PK/PD 68.4%,EUCAST 79%-84.2%)、大环内酯类(所有折点79%-84.2%)和头孢克洛(EUCAST 0%,PK/PD 52.6%)例外。
  • 突尼斯流感嗜血杆菌对多数抗生素敏感性≥86.5%,但对氨苄西林和阿莫西林(近三分之一β-内酰胺酶阳性)、甲氧苄啶/磺胺甲噁唑(51.4%-56.8%)、头孢克洛(PK/PD 1.4%)、头孢呋辛(EUCAST 4.1%)、大环内酯类(PK/PD 1.4%-2.7%)和头孢地尼(PK/PD 66.2%)例外。

关键数值与推荐

  • 应用EUCAST低剂量和高剂量折点(阿莫西林、阿莫西林/克拉维酸、氨苄西林、青霉素、头孢曲松、克拉霉素、红霉素、左氧氟沙星和甲氧苄啶/磺胺甲噁唑)首次在SOAR研究中量化了提高剂量对敏感性的影响。

临床怎么用

  • 这些敏感性数据可用于指导突尼斯、肯尼亚和摩洛哥社区获得性呼吸道感染的经验性抗生素治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of community-acquired respiratory tract infection (CA-RTI) isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2015-18 from Tunisia, Kenya and Morocco. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae isolates from Tunisia (n = 79), Kenya (n = 44) and Morocco (n = 19) and H. influenzae isolates (n = 74) from Tunisia only were collected and analysed. Low antibiotic susceptibility was observed in S. pneumoniae from Tunisia, with >90% susceptible only to the fluoroquinolones (all breakpoints), penicillin (CLSI IV and EUCAST high-dose) and ceftriaxone (CLSI, EUCAST high-dose and PK/PD breakpoints). In addition, isolate susceptibility in Kenya was >90% to amoxicillin and amoxicillin/clavulanic acid (CLSI and PK/PD breakpoints). Antibiotic activity was highest in Morocco, where ≥89.5% of pneumococci were susceptible to most antibiotics, excluding trimethoprim/sulfamethoxazole (68.4% by CLSI or PK/PD and 79%-84.2% by EUCAST), macrolides (79%-84.2% by all breakpoints) and cefaclor (0% by EUCAST and 52.6% by PK/PD). The majority (≥86.5%) of H. influenzae isolates from Tunisia were susceptible to most antibiotics by all available breakpoints, except ampicillin and amoxicillin (almost one-third were β-lactamase positive), trimethoprim/sulfamethoxazole (51.4%-56.8%), cefaclor (1.4% by PK/PD), cefuroxime (4.1% by EUCAST), macrolides (1.4%-2.7% by PK/PD) and cefdinir (66.2% by PK/PD). The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Low antibiotic susceptibility was observed in S. pneumoniae from Tunisia, but susceptibility was higher in isolates from Kenya and highest in those from Morocco. H. influenzae from Tunisia were highly susceptible to most antibiotics. These factors are important in decision making for empirical therapy of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Hammami A, Mezghani Maalej S, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337595. doi:10.1093/jac/dkaa081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。